Agilent (NYSE:A) has agreed to acquire privately held BioTek Instruments for $1.165B ($1.05B net with anticipated tax benefits).
The Winooski-VT-based life sciences gear maker generated $162M in revenues in fiscal 2018 and is expected to grow its top line 10% this year.
The deal should close in Q4. Agilent expects the transaction to be add $0.02 – 0.04 to non-GAAP EPS in fiscal 2020 and growing thereafter.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.